Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Theratechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.80.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Theratechnologies. This rating has held steady since September 2020, when it changed from a Hold consensus rating.
Theratechnologies Inc., a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States. The company was founded in 1993 and is headquartered in Montreal, Canada.